Anlotinib Versus Sunitinib as First‐Line Treatment for Metastatic Renal Cell Carcinoma: A Randomized Phase II Clinical Trial

BACKGROUND. Anlotinib is a tyrosine kinase inhibitor inhibiting angiogenesis. This multicenter, randomized phase II trial aimed to investigate the efficacy and safety of anlotinib in comparison with sunitinib as first‐line treatment for patients with metastatic renal cell carcinoma (mRCC). MATERIALS...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Zhou, Ai‐Ping, Bai, Yuxian, Song, Yan, Luo, Hong, Ren, Xiu‐Bao, Wang, Xiuwen, Shi, Benkang, Fu, Cheng, Cheng, Ying, Liu, Jiyan, Qin, Shukui, Li, Jun, Li, Hanzhong, Bai, Xianzhong, Ye, Dingwei, Wang, Jinwan, Ma, Jianhui
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons, Inc. 2019
Assuntos:
Genitourinary Cancer
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6693716/
https://ncbi.nlm.nih.gov/pubmed/30902918
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2018-0839
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados